Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corporation President and COO Michael Benkowitz reported option exercises and related share sales in United Therapeutics (UTHR) on January 12, 2026.
Trusts associated with him exercised 14,625 stock options at $117.76 per share and 7,875 stock options at $146.03 per share, then sold the same numbers of common shares at $479.5056 per share. These transactions were carried out under a Rule 10b5-1 trading plan entered into on June 3, 2025.
After these trades, one trust held 82,500 stock options and another held 44,440 stock options, and Benkowitz also held 2,648 shares of common stock directly. The filing notes that one trust is co‑managed by him and his spouse, while another is managed solely by him for the benefit of family members.
United Therapeutics president and COO Michael Benkowitz reported an option exercise and related share sales made through a trust. On January 5, 2026, a trust for his benefit exercised 14,625 stock options at an exercise price of $117.76 per share, receiving the same number of United Therapeutics common shares. The trust then sold those 14,625 shares in a series of open-market transactions at weighted-average prices that include $480.6821 and $494.2723, fully disposing of the shares acquired from the exercise.
The filing states that this option exercise and subsequent sales were carried out under a Rule 10b5-1 trading plan entered into on June 3, 2025. Following these transactions, a trust associated with Benkowitz continues to hold 97,125 stock options, and he also reports 2,648 shares of common stock held directly.
United Therapeutics Corp’s president and COO Michael Benkowitz, through a family trust, reported an option exercise and related share sales. On January 5, 2026, the trust exercised 7,875 stock options at an exercise price of $146.03 per share, receiving the same number of common shares. Those 7,875 shares of common stock were then sold in multiple open‑market transactions at weighted‑average prices ranging from about $480.32 to $494.41, all reported as indirect ownership "by Trust."
The filing states that the exercise and sales were made under a Rule 10b5‑1 trading plan entered into on June 3, 2025. After these sales, the trust no longer holds common stock, while Benkowitz is shown as directly owning 2,648 shares of common stock and indirectly holding 52,315 stock options through the trust.
United Therapeutics Corporation director Christopher Causey reported an option exercise and share sale. On January 6, 2026, he exercised stock options for 1,000 shares of common stock at an exercise price of $119.76 per share and acquired the underlying shares.
On the same date, he sold 1,000 shares of United Therapeutics common stock at a reported price of $510 per share. After these transactions, he directly owned 4,190 shares of common stock and 7,320 stock options. The filing notes that the option exercise and sale were carried out under a Rule 10b5-1 trading plan adopted on September 30, 2025.
A shareholder has filed a notice of proposed sale under Rule 144 for 1,000 shares of common stock of the issuer, to be sold through Morgan Stanley Smith Barney LLC on or about 01/06/2026 on the NASDAQ. The filing lists an aggregate market value of 510000.00 for these shares and notes that 43056599 shares of the issuer’s common stock were outstanding.
The 1,000 shares to be sold were acquired on 01/06/2026 via a stock option exercise from the issuer, paid in cash. The notice also reports that the same seller disposed of an additional 1,000 common shares on 01/02/2026 for 500014.60 in gross proceeds during the past three months. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer.
United Therapeutics Corporation’s CFO and Treasurer reported an option exercise and related share sales. On December 15, 2025, the executive exercised stock options for 3,517 shares of common stock at an exercise price of $146.03 per share and acquired those shares.
On the same date, the executive sold United Therapeutics common stock in multiple open-market transactions, with disclosed weighted average sale prices including $491.525 and $500.303 per share. After these transactions, the executive directly beneficially owns 8,142 shares of United Therapeutics common stock.
The option exercise and subsequent sales were carried out pursuant to a Rule 10b5-1 trading plan entered into on August 5, 2025. The report also corrects a prior administrative error by now including 24 shares acquired on September 4, 2025 under the United Therapeutics Corporation Stock Purchase Plan in the executive’s reported holdings.
United Therapeutics’ Chairperson & CEO, who is also a director, reported stock option exercises and related common stock sales under a pre-arranged Rule 10b5-1 trading plan. On December 15 and 16, 2025, the reporting person exercised 4,000 stock options at an exercise price of $120.26 on each day and sold the resulting shares in multiple open-market transactions at prices including $491.77, $495.1384, $492.4938, $494 and $497.17.
After these transactions, the reporting person held 130 shares of common stock directly, plus indirect holdings of 166 shares through a spouse and additional shares through family trusts, including 324,518, 258,117, 45,596 and 10,962 shares. The trades were made pursuant to a 10b5-1 trading plan entered on May 2, 2025, which will continue until the earlier of the exhaustion of a 294,000-share stock option tranche expiring on March 15, 2026 or December 31, 2025.
United Therapeutics President and COO reported insider transactions on 12/15/2025. The filing shows exercises of stock options into 14,625 and 7,875 shares of common stock held in family-related trusts, at exercise prices of $117.76 and $146.03 per share.
The common shares were then sold the same day in multiple trades under a Rule 10b5-1 trading plan entered on June 3, 2025, including sales at weighted average prices of $491.1817 and $500.3052. After these transactions, the trusts reported no remaining common shares, while 141,000 and 6,190 stock options remain indirectly owned.
United Therapeutics Corporation director reports stock option exercise and share sale. On 12/15/2025, the reporting person exercised 1,000 stock options at an exercise price of $101.80 per share and acquired an equal number of United Therapeutics common shares. On the same date, they sold 1,000 shares of common stock at a weighted average price of $495.9539 per share, with individual trades executed between $495.64 and $496.09. Following these transactions, the director beneficially owns 2,490 shares directly and 1,100 shares indirectly through a trust, as well as 3,910 stock options with a $101.80 exercise price expiring on 06/21/2026.
United Therapeutics reported that a company director sold 50 shares of common stock on 12/11/2025 at a price of $482.98 per share. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan that the insider entered into on September 11, 2025. Following this sale, the director beneficially owns 470 shares of United Therapeutics common stock held directly.